Psychedelic Therapeutics Clinical Trials Research Report 2024 Featuring Yale University, Johnson & Johnson, Shire Pharmaceuticals, Pfizer, Lykos, and UCB
September 13, 2024 06:55 ET
|
Research and Markets
Dublin, Sept. 13, 2024 (GLOBE NEWSWIRE) -- The "Clinical Trials: Psychedelic Therapeutics" report has been added to ResearchAndMarkets.com's offering.This report provides a review of global...
Avance Clinical Joins the Australian Clinical Trials Roadshow, Sharing Cost and Time Benefits for Early-Phase US Biotechs
September 13, 2024 05:23 ET
|
Avance Clinical
Avance Clinical will represent the CRO sector at the Australian Clinical Trials Roadshow to share the unparalleled time, cost and quality opportunities.
Biosplice Therapeutics Announces Initiation of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Trial Sponsored by the National Cancer Institute (NCI)
September 12, 2024 07:00 ET
|
Biosplice Therapeutics, Inc.
Biosplice Announces Initiation of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Trial Sponsored by the National Cancer Institute (NCI)
PharmAla to supply Johns Hopkins Medicine for Clinical Trial
September 11, 2024 08:55 ET
|
PharmAla Biotech
PharmAla completes sales agreement with Johns Hopkins Medicine, terminates contract with Red Light Holland, to present novel molecule at conference.
Precision Medicine Market Is Expected To Reach Revenue Of USD 225.7 Bn By 2033, At 11.6% CAGR: Dimension Market Research
September 10, 2024 11:03 ET
|
Dimension Market Research
New York, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Overview The Global Precision Medicine Market is to reach USD 83.9 billion by 2024 and is further anticipated to reach USD 225.7 billion by 2033...
NurExone Demonstrates Extended Therapeutic Window of ExoPTEN Post Spinal-Cord Injury in Preclinical Study
September 06, 2024 16:03 ET
|
NurExone Biologic Inc
NurExone demonstrates a longer timeframe of ExoPTEN treatment can be effectively administered post Spinal-Cord Injury
CD47 Inhibitor Drug Clinical Trials Market Outlook to 2028 - Emerging CD47 Inhibitor Clinical Trials Showcase Potential Cancer Treatment Breakthroughs
September 06, 2024 06:48 ET
|
Research and Markets
Dublin, Sept. 06, 2024 (GLOBE NEWSWIRE) -- The "Global CD47 Inhibitor Drug Clinical Trials Insight & Market Opportunity Outlook 2028" report has been added to ResearchAndMarkets.com's offering....
Turkey Cancer Drugs Clinical Trials Market Research 2024 Featuring OMEGA CRO, mediSMART, CRM-CRO, CROTURK, and Klinar CRO
September 05, 2024 04:21 ET
|
Research and Markets
Dublin, Sept. 05, 2024 (GLOBE NEWSWIRE) -- The "Turkey Cancer Drugs Clinical Trials Insight 2024" report has been added to ResearchAndMarkets.com's offering. Turkey presents an expanding...
Shuttle Pharma Provides Second Quarter 2024 Corporate Update
September 04, 2024 16:15 ET
|
Shuttle Pharmaceuticals Holdings, Inc.
GAITHERSBURG, Md., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company...
Down Syndrome Clinical Trials Review, 2024: Key Trends, Leading Companies, Latest Developments - Create Effective Counter Strategies to Gain a Competitive Advantage
September 04, 2024 10:42 ET
|
Research and Markets
Dublin, Sept. 04, 2024 (GLOBE NEWSWIRE) -- The "Down Syndrome - Global Clinical Trials Review, 2024" clinical trials has been added to ResearchAndMarkets.com's offering. This report offers a...